Use of venoarterial extracorporeal membrane oxygenation in fulminant chagasic myocarditis as a bridge to heart transplant

Andre Rodrigues Duraes1*, Fernando Augusto Marinho dos Santos Figueira2, Andre Rabelo Lafayette3 and Juliana de Castro Solano Martins4

1Specialist in cardiology by the Brazilian Society of Cardiology, Professor of Cardiology at Universidade do Estado da Bahia, Brazil
2Specialist in cardiovascular surgery by the Brazilian Society of Cardiovascular Surgery, Brazil
3Specialist in cardiology by the Brazilian Society of Cardiology, Brazil
4Medical Student at Universidade Federal da Bahia (UFBA), Brazil

A 17-year-old Brazilian male presented with progressive dyspnea for 15 days and worsening in the last 24 hours, being admitted on 04/04/15 in respiratory failure and cardiogenic shock with multiple organ dysfunction. Echocardiography showed left ventricle ejection fraction (LVEF) of 11%, severe diffuse hypokinesia and systolic pulmonary artery pressure (sPAP) of 50 mmHg, developing need for hemodynamic support with dobutamine (20 mcg/kg/min) and noradrenaline (1,7 mcg/kg/min). After 48 hours with no clinical or hemodynamic improvement, extracorporeal membrane oxygenation (ECMO) was implanted. Hemodynamic (noradrenaline dropped to 0,21 mcg/kg/min), systemic perfusion (lactate of17 mmol/L dropped to 2,5 mmol/L and increase diuresis volume), renal (serum creatinine from 6.5 to 1.2 mg/dL) and liver function (international normalized ratio 8.5 to 1.2) improvement was presented, but without cardiac function recovery after 72 hours opting for transfer to another hospital.

Air transport was conducted from Salvador to Recife on 09/04/15 (travelled distance of 466 miles). Heart transplant was conducted on 11/04/15, with excellent performance, rapid recovery of liver and kidney function and good graft function. Histopathology of the explanted heart showed chronic active myocarditis and amastigotes of Trypanosoma cruzi (Figure 1), showing chagasic cardiomyopathy.

Myocarditis is an inflammatory disease due to infectious or non-infectious conditions. Clinical manifestation is variable, ranging from subclinical presentation to refractory heart failure and cardiogenic shock [1]. Mechanical circulatory support with intra-aortic balloon or ventricular assist devices should be considered in cases refractory to medical therapy [2]. Several reports suggest that the use of ECMO in patients presenting severe and refractory myocarditis is an option as a bridging therapy to heart transplant when there is no spontaneous recovery of ventricular function [3,4]. The venoarterial ECMO can be implanted percutaneously at the bedside and can be kept for several weeks with proper care. It is the preferred device when biventricular dysfunction is presented and often promotes rapid improvement of hemodynamic status, oxygenation parameters and organ function [5]. In face of heart function improvement, the mechanical support device can be progressively withdrawn, but when cardiac function impairment is maintained, the treatment of choice would be a long-term device or heart transplant [3,4]. In the presented case, ECMO was used on a patient with multiple organ failure secondary to a defined and refractory cardiogenic shock. The benefit of the method was unquestionable even in advance stages of renal and liver failure. The patient presented partial recovery of the affected systems, making possible the implementation of the definitive therapy to severe myocarditis: heart transplant. In a 6-month follow-up outpatient consult, the patient presented himself in good health.

Acknowledgments

We would like to thank the heart transplant team at the Hospital

Figure 1. Patient and ECMO equipment positioning during air transport from Salvador to Recife (Brazil).

Histology of explanted heart sample. Panel A, photomicrograph (×400) of an haematoxylin and eosin stained sample. In Panel B, at this magnification (×1000) the organisms (amastigotes of Trypanosoma cruzi) within a myocyte (arrow) and the adjacent inflammatory response are more clearly seen.
Ana Nery and the Instituto de Medicina Integral Professor Fernando Figueira.

Disclosure statement

The authors have no conflicts of interest to disclose.

References


